| Not Yet Recruiting | Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer NCT07243067 | Mayo Clinic | — |
| Not Yet Recruiting | Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Cl NCT07516366 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Su NCT07037004 | City of Hope Medical Center | Phase 2 |
| Not Yet Recruiting | Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell NCT07187869 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy NCT06863311 | Karie Runcie | Phase 2 |
| Recruiting | Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Ot NCT07227415 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therap NCT07469683 | Yonsei University | Phase 2 |
| Recruiting | Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma NCT07223541 | University of Oklahoma | Phase 2 |
| Recruiting | Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cel NCT07300241 | Neomorph, Inc | Phase 1 |
| Recruiting | Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear NCT07187778 | M.D. Anderson Cancer Center | Phase 2 |
| Not Yet Recruiting | Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcin NCT07023432 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC NCT07389629 | Sun Yat-sen University | Phase 2 |
| Withdrawn | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC NCT07084909 | Lantheus Medical Imaging | Phase 2 / Phase 3 |
| Not Yet Recruiting | Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases NCT07043608 | Kelly Fitzgerald, MD | Phase 2 |
| Enrolling By Invitation | 68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Ma NCT07101900 | Peking Union Medical College Hospital | Phase 2 |
| Not Yet Recruiting | Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy NCT06976021 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Recruiting | Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remov NCT06661720 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Suspended | Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC NCT06860386 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known NCT06805825 | Novelty Nobility, Inc. | Phase 1 |
| Active Not Recruiting | A Phase 1/2 Trial of ADI-270 in ccRCC NCT06480565 | Adicet Therapeutics | Phase 1 / Phase 2 |
| Suspended | 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC NCT06649682 | Peking Union Medical College Hospital | Phase 1 |
| Recruiting | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study NCT06750419 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 |
| Recruiting | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent NCT06447103 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Recruiting | 68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma NCT06519760 | Peking University First Hospital | N/A |
| Recruiting | Combination of Toripalimab and JS004 Therapy for ccRCC NCT06690697 | Fudan University | Phase 2 |
| Recruiting | 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC. NCT06613269 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Recruiting | Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer NCT06195150 | IRCCS San Raffaele | — |
| Terminated | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies NCT06052852 | Bolt Biotherapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell C NCT06049576 | City of Hope Medical Center | Phase 1 |
| Completed | Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC NCT06138496 | Sun Yat-sen University | Phase 2 |
| Unknown | 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Mass NCT05879510 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | 68Ga-NY104 PET/CT in Patients With Metastasis/Recurrence Clear Cell Renal Cell Carcinoma Suspicion NCT05879497 | Peking Union Medical College Hospital | Phase 2 |
| Terminated | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748 | NiKang Therapeutics, Inc. | Phase 2 |
| Recruiting | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients NCT05663710 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Re NCT05861778 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Completed | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors NCT05795595 | CRISPR Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors NCT05536141 | Arcus Biosciences, Inc. | Phase 1 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab NCT05363631 | Mohammed Milhem | Phase 1 / Phase 2 |
| Recruiting | Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in L NCT06088134 | Mingzhao Xiao | — |
| Active Not Recruiting | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders NCT05286294 | Oslo University Hospital | Phase 2 |
| Recruiting | Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma NCT05433142 | Xencor, Inc. | Phase 1 |
| Completed | 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients NCT05432947 | Peking Union Medical College Hospital | N/A |
| Terminated | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) NCT05121948 | HiberCell, Inc. | Phase 1 |
| Active Not Recruiting | Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer NCT05239533 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma NCT05214885 | Qianfoshan Hospital | — |
| Active Not Recruiting | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies NCT05199272 | 23andMe, Inc. | Phase 1 / Phase 2 |
| Completed | A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma NCT05728515 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Terminated | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT05119335 | NiKang Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Ca NCT04995016 | Tianjin Medical University Second Hospital | Phase 2 |
| Recruiting | [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma NCT04989959 | Orhan Kemal Oz | Phase 1 |
| Unknown | A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer NCT04958473 | Tianjin Medical University Second Hospital | Phase 2 |
| Active Not Recruiting | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear C NCT04810078 | Bristol-Myers Squibb | Phase 3 |
| Terminated | Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab NCT04779151 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 2 |
| Terminated | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal NCT04300140 | Aravive, Inc. | Phase 1 / Phase 2 |
| Terminated | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery NCT04370509 | University of California, San Francisco | Phase 2 |
| Completed | ABEMA Alone or in COMBO With MK-6482 NCT04627064 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT04169711 | Arrowhead Pharmaceuticals | Phase 1 |
| Completed | Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or O NCT04518046 | Mirati Therapeutics Inc. | Phase 1 |
| Completed | Evaluation of Safety, Biodistibution and Sensitivity/Specificity of PET/CT Imaging With 89Zr-TLX250 in Subject NCT04496089 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Active Not Recruiting | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) f NCT04071223 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors NCT04374877 | Coherus Oncology, Inc. | Phase 1 |
| Recruiting | Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma NCT04053855 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Completed | AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC NCT04006405 | Elypta | — |
| Completed | 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study NCT03849118 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 3 |
| Active Not Recruiting | Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer NCT04022343 | Emory University | Phase 2 |
| Active Not Recruiting | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients NCT03793166 | National Cancer Institute (NCI) | Phase 3 |
| Unknown | Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma NCT03987698 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Terminated | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors NCT03875313 | Calithera Biosciences, Inc | Phase 1 / Phase 2 |
| Completed | CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer NCT03829111 | City of Hope Medical Center | Phase 1 |
| Active Not Recruiting | Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 NCT03284385 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Completed | A CT-BASED Deep Learning Model for Predicting WHO/ISUP Pathological Grades of Clear Cell Renal Cell Carcinoma NCT06559046 | Ting Huang | — |
| Completed | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma NCT03680521 | Mirati Therapeutics Inc. | Phase 2 |
| Active Not Recruiting | Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue NCT06339138 | Mayo Clinic | — |
| Completed | Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer NCT03473730 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Withdrawn | Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Met NCT03149159 | Medical University of South Carolina | Phase 2 |
| Active Not Recruiting | Prior Axitinib as a Determinant of Outcome of Renal Surgery NCT03438708 | University of California, San Diego | Phase 2 |
| Terminated | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastat NCT03334409 | Academic and Community Cancer Research United | Phase 2 |
| Active Not Recruiting | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer NCT03308396 | Ajjai Alva, MD | Phase 1 / Phase 2 |
| Unknown | Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Lin NCT03592199 | Instituto do Cancer do Estado de São Paulo | Phase 2 |
| Terminated | Enzalutamide Before Surgery in Treating Patients With Kidney Cancer NCT02885649 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Completed | CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) NCT03163667 | Calithera Biosciences, Inc | Phase 2 |
| Active Not Recruiting | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer NCT03092856 | University of Southern California | Phase 2 |
| Terminated | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma NCT03185182 | Region Skane | Phase 2 |
| Withdrawn | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma NCT03035630 | Guru Sonpavde | Phase 2 |
| Completed | MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK NCT03108066 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 |
| Completed | Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer NCT03015740 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms T NCT02581384 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Terminated | Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma NCT02923531 | X4 Pharmaceuticals | Phase 1 / Phase 2 |
| Active Not Recruiting | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) NCT02974738 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Terminated | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clea NCT02837991 | Celldex Therapeutics | Phase 1 |
| Completed | Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA NCT02607553 | GenSpera, Inc. | Phase 2 |
| Terminated | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery NCT02595918 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma NCT02667886 | X4 Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer NCT02626130 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma NCT02575222 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors NCT02700568 | Kidney Cancer Research Bureau | Phase 2 |
| Terminated | Safety Study of MGD009 in B7-H3-expressing Tumors NCT02628535 | MacroGenics | Phase 1 |
| Withdrawn | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer NCT02307474 | Case Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourin NCT02496208 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney NCT02210117 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma ( NCT02293980 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Completed | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combinati NCT02118337 | MedImmune LLC | Phase 1 / Phase 2 |
| Terminated | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer NCT01943188 | Stanford University | Phase 1 |
| Unknown | Value of Various Chemokines in the Detection and Follow up of RCC NCT02022787 | Carmel Medical Center | — |
| Completed | Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or M NCT01835158 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer NCT01826877 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cance NCT01684397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer NCT01727089 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Studying Biomarkers in Samples From Younger Patients With Kidney Cancer NCT01642095 | Children's Oncology Group | — |
| Active Not Recruiting | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease Aft NCT01575548 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patien NCT01599832 | University of Chicago | N/A |
| Unknown | 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC NCT01791387 | Auckland District Health Board | Phase 2 |
| Completed | AMG 172 First in Human Study in Patients With Kidney Cancer NCT01497821 | Amgen | Phase 1 |
| Completed | Investigating Patient Satisfaction With Oral Anti-Cancer Treatment NCT02247583 | KU Leuven | — |
| Completed | Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer NCT01157091 | City of Hope Medical Center | Phase 2 |
| Completed | Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies NCT01243359 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After NCT01198158 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer NCT01158222 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Grow NCT01141569 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer NCT01158521 | Case Comprehensive Cancer Center | Phase 2 |
| Terminated | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does N NCT01582009 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer NCT01038778 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) NCT01069770 | Korean Urological Oncology Society | Phase 2 |
| Completed | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer NCT00378703 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 NCT00602862 | Radboud University Medical Center | N/A |
| Completed | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tu NCT00499135 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer NCT00408902 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors NCT00335556 | Children's Oncology Group | Phase 2 |
| Completed | Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery NCT00326898 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer NCT00303862 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer NCT00324870 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer NCT00126659 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer NCT00182702 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses. NCT00199888 | Ludwig Institute for Cancer Research | Phase 1 |
| Completed | Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney NCT00126594 | National Cancer Institute (NCI) | Phase 2 |
| Completed | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00112840 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer NCT00126503 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer NCT00098618 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00101114 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma NCT00193258 | SCRI Development Innovations, LLC | Phase 1 / Phase 2 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Available | 89Zr-DFO-girentuximab Expanded Access Program (EAP) NCT06090331 | Telix Pharmaceuticals (Innovations) Pty Limited | — |